Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Glaxo, Bristol Offering Rx Discounts Through Citizens Health Card Program

Executive Summary

GlaxoSmithKline and Bristol-Myers Squibb are offering point-of-sale discounts on prescriptions for members of the Citizens Health drug discount card program.

You may also be interested in...



Medicare Rx Card Rule To Be Published By End Of November – CMS’ Scully

The Centers for Medicare and Medicaid Services is planning to publish a proposed rule on a Medicare drug discount card plan by the end of November

Medicare Rx Card Rule To Be Published By End Of November – CMS’ Scully

The Centers for Medicare and Medicaid Services is planning to publish a proposed rule on a Medicare drug discount card plan by the end of November

Iowa Rx Discount Card Program Negotiating Manufacturer Discounts

The "Iowa Priority" drug discount program is discussing discounts for seniors with manufacturers

Related Content

Latest Headlines
See All
UsernamePublicRestriction

Register

PS038583

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel